Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Pelthos Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +9 vs. Q2 2025
- Shares held
- 462.8K
- +314.9K (+212.9%) vs. Q2 2025
- Total value
- $13.0M
- +$12.8M (+6,818.1%) vs. Q2 2025
- New holders
- 10
- 1 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTHS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $37.4M |
| Q1 2026 | 17 | $19.2M |
| Q4 2025 | 15 | $27.9M |
| Q3 2025 | 14 | $13.0M |
| Q2 2025 | 5 | $187.3K |
| Q1 2025 | 9 | $846.2K |
| Q4 2024 | 4 | $16.0K |
| Q3 2024 | 5 | $59.6K |
| Q2 2024 | 5 | $290.3K |
| Q1 2024 | 1 | $659.9K |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Pelthos Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 1 | $28 | 0.00% | +1 | New |
| Citigroup Inc | 1 | $28 | 0.00% | +1 | New |
| Bank of America Corp | 11 | $308 | 0.00% | −8−42.1% | Reduced |
| UBS Group AG | 137 | $3.84K | 0.00% | −515−79.0% | Reduced |
| Tower Research Capital LLC (TRC) | 827 | $23.2K | 0.00% | +742+872.9% | Added |
| Steward Partners Investment Advisory, LLC | 1,910 | $53.5K | 0.00% | +1,910 | New |
| Persistent Asset Partners Ltd | 2,403 | $67.3K | 0.05% | +2,403 | New |
| Knott David M Jr | 6,112 | $171.1K | 0.07% | +6,112 | New |
| Geode Capital Management, LLC | 10,330 | $289.2K | 0.00% | −105−1.0% | Reduced |
| Diadema Partners LP | 10,498 | $293.9K | 0.20% | +10,498 | New |
| Boothbay Fund Management, LLC | 21,245 | $594.9K | 0.02% | +21,245 | New |
| Ikarian Capital, LLC | 62,451 | $1.75M | 0.40% | +62,451 | New |
| Vanguard Group Inc | 66,836 | $1.87M | 0.00% | +66,836 | New |
| Murchinson Ltd. | 280,000 | $7.84M | 1.52% | +280,000 | New |
| Millennium Management LLC | 0 | $0 | 0.00% | −136,712−100.0% | Sold out |